Gabriel Hortobagyi, M.D.
Stories this photo appears in:
Ribociclib added to endocrine therapy extends survival in postmenopausal patients with metastatic breast cancer
A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. This is the first demonstration of a survival advantage with a front-line CDK4/6 inhibitor in postmenopausal patients with HR+/HER 2- advanced breast cancer.
